Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-02-06
2007-02-06
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S009100, C424S236100, C514S012200, C530S350000, C435S325000, C435S069100, C435S320100, C536S023700
Reexamination Certificate
active
10715810
ABSTRACT:
The present invention relates to rescue agents for use in the treatments of toxin intoxication—for example botulinum intoxication, which can result from food poisoning, an act of bioterrorism, or from accidental overdose in the course of treatment. In some embodiments, the rescue agents comprise at least one of an inactivebotulinumtoxin and a modified nontoxic nonhemagglutinin. The present invention also provides for glycosylated active and inactive toxins and methods of using same.
REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 6051239 (2000-04-01), Simpson et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6203794 (2001-03-01), Dolly et al.
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan
patent: 6312708 (2001-11-01), Donovan
patent: 6328977 (2001-12-01), Donovan
patent: 6358513 (2002-03-01), Voet et al.
patent: 6365164 (2002-04-01), Schmidt
patent: 6395277 (2002-05-01), Graham
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: WO02/089834 (2002-11-01), None
Park and Simpson, “Inhalational poisoning botulinium toxin and inhalation vaccination with its heavy-chain component,” Infect. Immun. (2003) 71:1147-1154.
Atassi and Oshima, “Structure, activity and immune (T and B cell) recognition of botulinum neurotoxins,” Crit. Rev. Immunol. (1999) 19:219-260.
Marchese Ragona, et al., “Management of parotid sialocele with botulinum toxin,” The Laryngoscope (1999) 109:1344-1346.
Wiegand, et al., “125-I labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection,” Naunyn-Schmiedeberg's Arch. Pharmacol. (1976) 292:161-165.
Habermann, “125-I labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord,” Naunyn-Schmiedeberg's Arch. Pharmacol. (1974) 281:47-56.
Moyer, et al., “Botulinum Toxin Type B: Experimental and Clinical Experience,” in Therapy with Botlinum Toxin, Jankovic, ed., 1994, pp. 71-84.
Gonelle-Gispert, “SNAP-25a and -25b isoforms are both expressed in insulin secreting cells and can function in insulin secretion,” Biochem. J. (1999) 339:159-165.
International Conference on Botulinum Toxin: Basic Science and Clinical Therapeutics, Mov. Disord. (1995) 10:361-408.
Haberman, et al., “Tetanus toxin and botulinum A and C neurotoxins inhibit noradrenaline release from cultured mouse brain,” J. Neurochem. (1988) 51:522-527.
Sanchez-Prieto, et al., “Botulinum toxin A blocks glutamate exocytosis from guinea pig cerebral cortical synaptosomes,” Eur. J. Biochem. (1987) 165:675-681.
Pearce, “Pharmacologic characterization of botuinum toxin for basic science and medicine,” Toxicon (date) 35:1373-1412.
Bigalke, et al., “Botulinum A neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal cord neurons in culture,” Brain Res. (1985) 360:318-324.
Habermann, “Inhibition by tetanus and botulinum A toxin of the relaease of [3H] noradrenaline and [3H] GABA from rat brain homogenate,” Experientia (1988) 44:224-226.
Bigalke, et al., “Tetanus toxin and botulinum A toxin inhibit release and uptake of various transmitters as studied with particulate preparations from rat brain and spinal cord,” Naunyn-Schmiedelberg's Arch. Pharmacol. (1981) 316:244-251.
Jancovic, et al., eds., “Therapy with Botulinum Toxin,” New York, Marcel Dekkar, 1994. p. 5.
Schantz, et al., “Properties and use of botulinum toxin and other microbial neurotoxins in medicine,” Microbial Rev. (1992) 56:80-99.
Sloop, et al., “Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for two weeks before use,” Neurology (1997) 48:249-253.
Galbiati, et al., “Identification, sequence and developmental expression of invertebrate flotillins from Drosophila melanogaster,” Gene (1998) 210:229-237.
Li, et al., “Src tyrosine kinases, Galpha subunits, and H-ras share a common membrane-anchored scaffolding protein, caveolin,” J. Biol. Chem. (1996) 271:29182-29190.
Ishizaka, et al., “Angiotensin II tyhpe receptor: Relationship with caveolae and caveolin after initial agonist simulation,” Hypertension (1998) 32:459-466.
Ju, et al., “Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-acid synthase,” J. Biol. Chem. (1998) 273:24025-24029.
Webb, et al., “SR-BII, and isoform of the scavenger receptor BI containing an alternate cytoplasmic tail, mediates lipid transfer between high density lipoprotein and cells,” J. Biol. Chem. (1998) 273:15241-15248.
Drab, et al., “Loss of caveolae, vascular dysfunction, and prliminary defects in caveolin-1 gene-disrupted mice,” Science (2001) 293:2449-2452.
Bouillot, et al., “Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties,” J. Biol. Chem. (1996) 271:7640-7644.
Razani, et al., “Caveolae: From cell biology to animal physiology,” Pharmacol. Rev. (2002) 54:431-467.
Li, et al., “Phosphorylation of caveolin by src tyrosine kinases,” J. Biol. Chem. (1996) 271:3863-3868.
Razani and Lisanti, “Caveolin-deficient mice:insights into caveolar function and human disease,” J. Clin. Investig. (2001) 108:1553-1561.
Garcia-Cardena, et al., “Dissecting the Interaction between nitric oxide synthase (NOS) and caveolin,” J. Biol. Chem. (1997) 272:25437-25440.
Sotgia, et al., “Intracellular retention of glycophosphatidylinositol-linked proteins in caveolin-deficient cells,” Mol. Cell. Biol. (2002) 22:3905-3926.
Frank, et al., “Influence of caveolin-1 on cellular cholesterol efflux mediated by high-density lipoproteins,” Am. J. Physiol. Cell Physiol. (2001) 280:C1204-C1214.
Galbiati, et al., “Caveolin-1 expression negatively reguates cell cycle progression by inducing G0/G1 arrest via a p53/p21WAF1/Cip1-dependent mechanism,” Mol. Biol. Cell. (2001) 12:2229-2244.
Frank, et al., “Adenovirus-mediated expression of cavolin-1 in mouse liver increases plasma high-density lipoprotein levels,” Biochemistry (2001) 40:10892-10900.
Lee, et al., “Src-induced phosphorylation of caveolin-2 on tyrosine 19,” J. Biol. Chem. (2002) 277:34556-34567.
Couet, et al., “Identification of peptide and protein ligands for the caveolin-scaffolding domain,” J. Biol. Chem. (1997) 272:6525-6533.
Lee, et al., “Constitutive and growth factor-regulated phosphorylation of caveolin-1 ocurrs at the same site (Tyr-14) in vivo: identification of a c-src/cav-1/grb7 signalling cassette,” Mol. Endocrinol. (2000) 14:1750-1775.
Sato, et al., “Reconstitution of src-dependent phospholipase Cgamma phosphorylation and transient calcium release by using membrane rafts and cell-free extracts from Xenopus eggs,” J. Biol. Chem (2003) 278:38413-38420.
Gargalovic and Dory, “Cellular apoptosis is associated with increased caveolin-1 expression in macrophages,” J. Lipid Res. (2003) 44:1622-1632.
Hamer, et al., “Rational design of drugs that induce human immunodeficiency virus replication,” J. Virol. (2003) 77:10227-10236.
McIntosh, et al., “Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery,” Proc. Natl. Acad. Sci. USA (2002) 99:1996-2001.
Li, et al., “Baculovirus-based
Aoki Kei Roger
Francis Joseph
Li Shengwen
Steward Lance E.
Allergan Inc.
German Joel B.
Kam Chih-Min
Stathakis Dean G.
Voet Martin A.
LandOfFree
Rescue agents for treating botulinum toxin intoxications does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rescue agents for treating botulinum toxin intoxications, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rescue agents for treating botulinum toxin intoxications will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3882477